SG11201811737SA - Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease - Google Patents

Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease

Info

Publication number
SG11201811737SA
SG11201811737SA SG11201811737SA SG11201811737SA SG11201811737SA SG 11201811737S A SG11201811737S A SG 11201811737SA SG 11201811737S A SG11201811737S A SG 11201811737SA SG 11201811737S A SG11201811737S A SG 11201811737SA SG 11201811737S A SG11201811737S A SG 11201811737SA
Authority
SG
Singapore
Prior art keywords
international
indianapolis
ethoxy
amino
indiana
Prior art date
Application number
SG11201811737SA
Other languages
English (en)
Inventor
Jorge Alsina-Fernandez
Lili Guo
John Lee
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG11201811737SA publication Critical patent/SG11201811737SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
SG11201811737SA 2016-07-15 2017-07-13 Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease SG11201811737SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662362711P 2016-07-15 2016-07-15
US201662431682P 2016-12-08 2016-12-08
US201762491385P 2017-04-28 2017-04-28
PCT/US2017/041922 WO2018013803A1 (fr) 2016-07-15 2017-07-13 Nouveaux analogues d'urocortine-2 modifiés par acides gras pour le traitement du diabète et de maladies rénales chroniques

Publications (1)

Publication Number Publication Date
SG11201811737SA true SG11201811737SA (en) 2019-01-30

Family

ID=59501524

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811737SA SG11201811737SA (en) 2016-07-15 2017-07-13 Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease

Country Status (24)

Country Link
US (1) US10894817B2 (fr)
EP (1) EP3484495B1 (fr)
JP (1) JP2019525919A (fr)
KR (1) KR20190017982A (fr)
CN (1) CN109475592B (fr)
AU (1) AU2017295708B2 (fr)
BR (1) BR112018076693A2 (fr)
CA (1) CA3030965C (fr)
CL (1) CL2019000043A1 (fr)
CO (1) CO2018014026A2 (fr)
CR (1) CR20190015A (fr)
DO (1) DOP2019000007A (fr)
EC (1) ECSP19003047A (fr)
ES (1) ES2901477T3 (fr)
IL (1) IL264025A (fr)
JO (1) JOP20170153A1 (fr)
MA (1) MA45673A (fr)
MX (1) MX2019000661A (fr)
PE (1) PE20190470A1 (fr)
PH (1) PH12019500074A1 (fr)
SG (1) SG11201811737SA (fr)
SV (1) SV2019005808A (fr)
TW (1) TW201811821A (fr)
WO (1) WO2018013803A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
CN114456176B (zh) 2016-03-28 2024-08-30 因赛特公司 作为tam抑制剂的吡咯并三嗪化合物
KR102739325B1 (ko) 2017-09-27 2024-12-09 인사이트 코포레이션 Tam 억제제로서 유용한 피롤로트리아진 유도체의 염
WO2019140030A1 (fr) * 2018-01-12 2019-07-18 Eli Lilly And Company Polythérapie
WO2019140021A1 (fr) * 2018-01-12 2019-07-18 Eli Lilly And Company Polythérapie
WO2019140025A1 (fr) * 2018-01-12 2019-07-18 Eli Lilly And Company Polythérapie
WO2019140023A1 (fr) * 2018-01-12 2019-07-18 Eli Lilly And Company Polythérapie
WO2019140024A1 (fr) * 2018-01-12 2019-07-18 Eli Lilly And Company Polythérapie
US11241438B2 (en) 2018-06-29 2022-02-08 Incyte Corporation Formulations of an AXL/MER inhibitor
US20200027555A1 (en) * 2018-07-17 2020-01-23 Lewis Pharmaceutical Information, Inc. Patient centric drug analysis platform
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
MX2023002087A (es) 2020-08-19 2023-03-23 Sanofi Sa Agonistas del receptor crf2 y su uso en terapia.
WO2022159395A1 (fr) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions et procédés pour le traitement de troubles métaboliques et hépatiques
WO2023285334A1 (fr) 2021-07-12 2023-01-19 Novo Nordisk A/S Nouveaux dérivés d'urocortine 2 modifiés par un acide gras et leurs utilisations
IL311411A (en) 2021-09-15 2024-05-01 Viking Therapeutics Inc Preparations and methods for the treatment of metabolic and liver disorders
EP4234574A1 (fr) 2022-02-23 2023-08-30 Corteria Pharmaceuticals Agonistes du récepteur crf2 et leur utilisation en thérapie
WO2025104264A1 (fr) 2023-11-17 2025-05-22 Gubra A/S Polypeptides sélectifs de hcrhr2
TW202540149A (zh) * 2023-11-17 2025-10-16 美商美國禮來大藥廠 用於治療糖尿病或肥胖症之化合物
WO2026064495A1 (fr) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Peptides chimiquement modifiés et leur utilisation
WO2026064486A1 (fr) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Peptides chimiquement modifiés et leur utilisation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2193072A1 (fr) 1994-06-14 1995-12-21 Derek Chalmers Recepteurs du facteur2 liberant la corticotropine
EP0845035A2 (fr) * 1995-06-13 1998-06-03 The Salk Institute For Biological Studies Peptides d'urocortine
US20040034882A1 (en) 1999-07-15 2004-02-19 Vale Wylie W. Corticotropin releasing factor receptor 2 deficient mice and uses thereof
CN1484650B (zh) * 2000-08-04 2012-12-12 研究发展基金会 尿皮质素蛋白及其用途
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
NZ524477A (en) 2001-03-15 2004-11-26 Res Dev Foundation Urocortin-III and uses thereof
US7192923B2 (en) * 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
GR1004664B (en) 2002-11-26 2004-09-02 Bionature E A Ltd The charakteristics and advantages of our invention are illustrated by the following description, methods and results of our research, attached figures and supporting references
WO2005103690A2 (fr) 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostic et therapeutique de maladies associees au recepteur de l'hormone de liberation de la corticotropine 2 (crhr2)
CA2576435A1 (fr) 2004-08-09 2006-03-23 Research Development Foundation Modulateurs de recepteurs couples a la proteine g b1 fondes sur une structure
WO2006086402A2 (fr) 2005-02-08 2006-08-17 Research Development Foundation Compositions et methodes se rapportant aux recepteurs couples a la proteine g soluble (sgpcr)
WO2007090087A2 (fr) 2006-01-27 2007-08-09 Research Development Foundation Inhibiteurs du recepteur 2 du facteur de liberation de la corticotrophine et ses utilisations
US7982018B2 (en) * 2006-10-16 2011-07-19 Conjuchem, Llc Modified corticotropin releasing factor peptides and uses thereof
EP2167094A2 (fr) 2007-06-13 2010-03-31 Research Development Foundation Procédés pour le traitement et la prévention de tauopathies et l'amyloïdose de bêta-amyloïde en modulant la signalisation de récepteur crf
AU2009313619A1 (en) 2008-11-04 2010-05-14 Janssen Pharmaceutica Nv CRHR2 peptide agonists and uses thereof
WO2011025905A1 (fr) * 2009-08-28 2011-03-03 Research Development Foundation Analogues d'urocortine 2 et leurs utilisations
WO2011057027A2 (fr) 2009-11-04 2011-05-12 Janssen Pharmaceutica Nv Méthode de traitement de l'insuffisance cardiaque avec des peptides de type stresscopine
WO2011092293A2 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
US9314506B2 (en) 2011-10-24 2016-04-19 Research Development Foundation Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors
CA2943751A1 (fr) 2014-04-03 2015-10-08 The Regents Of The University Of California Administration systemique de vecteurs de virus codant pour l'urocortine-2 et genes associes pour traiter un dysfonctionnement cardiaque lie au diabete et une insuffisance cardiaque congestive
AR104932A1 (es) * 2015-06-22 2017-08-23 Lilly Co Eli Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
WO2017220706A1 (fr) * 2016-06-22 2017-12-28 Novo Nordisk A/S Compositions pharmaceutiques de dérivés de fgf21 et leurs utilisations

Also Published As

Publication number Publication date
CN109475592A (zh) 2019-03-15
EP3484495A1 (fr) 2019-05-22
PH12019500074A1 (en) 2019-07-29
MX2019000661A (es) 2019-05-15
US20180016318A1 (en) 2018-01-18
ECSP19003047A (es) 2019-01-31
TW201811821A (zh) 2018-04-01
CR20190015A (es) 2019-02-27
DOP2019000007A (es) 2019-04-15
EP3484495B1 (fr) 2021-09-08
AU2017295708A1 (en) 2018-12-20
SV2019005808A (es) 2019-04-04
KR20190017982A (ko) 2019-02-20
BR112018076693A2 (pt) 2019-04-02
CL2019000043A1 (es) 2019-06-07
PE20190470A1 (es) 2019-04-04
MA45673A (fr) 2021-05-26
ES2901477T3 (es) 2022-03-22
IL264025A (en) 2019-01-31
CO2018014026A2 (es) 2019-01-18
CA3030965C (fr) 2022-04-26
WO2018013803A1 (fr) 2018-01-18
CN109475592B (zh) 2022-08-09
US10894817B2 (en) 2021-01-19
JOP20170153A1 (ar) 2019-01-30
JP2019525919A (ja) 2019-09-12
CA3030965A1 (fr) 2018-01-18
AU2017295708B2 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201909022PA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201803958WA (en) Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11201907232XA (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
SG11201810371XA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201804729RA (en) Methods and compositions for treating a serpinc1-associated disorder
SG11201807912SA (en) Vaccine against rsv
SG11201809126RA (en) Aromatic sulfonamide derivatives
SG11201900844UA (en) Amino pyrimidine ssao inhibitors
SG11201807543YA (en) Hepatitis b antiviral agents
SG11201908598PA (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
SG11201408054RA (en) Pegylated oxm variants
SG11202000266VA (en) Quinoline derivatives for treating infections with helminths
SG11201809764XA (en) Humanized anti-il-1r3 antibodies
SG11201901206SA (en) Trimer stabilizing hiv envelope protein mutations
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201408511QA (en) Liquid preparations of amines and organic acids stabilized by salts
SG11201810726QA (en) Composition comprising self-assembling peptides for use in treatment of gingivitis, periodontitis and/or peri-implantitis
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201908660RA (en) N-substituted indole derivatives
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds